Publications by authors named "Laura Finneran"

Claim this Profile
P
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.
Anna M Kirby, Laura Finneran, Clare L Griffin, Adrian M Brunt, Fay H Cafferty

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Pasquale Rescigno, Nuria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply.
Christopher Nutting, Laura Finneran, Justin Roe, Imran Petkar, Keith Rooney

Lancet Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Christopher Nutting, Laura Finneran, Justin Roe, Mark A Sydenham, Matthew Beasley

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Javier Pascual, Joline S J Lim, Iain R Macpherson, Anne C Armstrong, Alistair Ring, Laura Finneran

Cancer Discov· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J Harris, Laura Finneran

Lancet Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers.
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, Stephen J Pettitt, Joline S J Lim, Laura Finneran

Cancer Discov· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis